Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cilazapril→

Cilazapril Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
88768-40-5
Molecular formula
C22H31N3O5
Molecular weight
417.5 g/mol
Drug class
Angiotensin-converting enzyme (ACE) inhibitorantihypertensive and cardiovascular agent
Mechanism of action
Prodrug hydrolysed to cilazaprilat, which inhibits ACE and reduces conversion of angiotensin I to angiotensin II, lowering vasoconstriction and aldosterone secretion.
Indications / reported uses
  • Treatment of hypertension in adults in countries where cilazapril is authorised
  • Treatment of heart failure in selected patients under country-specific product information; dosing and monitoring are required

Sources: NLM MeSH — Cilazapril · PubMed — Cilazapril ACE inhibitor · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cilazapril Environmental Risk Assessment (ERA) (the Cilazapril ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.